NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free NTLA Stock Alerts $27.07 +0.05 (+0.19%) (As of 02:22 PM ET) Add Compare Share Share Today's Range$26.61▼$27.3750-Day Range$23.82▼$32.8052-Week Range$22.67▼$47.48Volume363,102 shsAverage Volume1.57 million shsMarket Capitalization$2.60 billionP/E RatioN/ADividend YieldN/APrice Target$67.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Intellia Therapeutics alerts: Email Address Intellia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside150.6% Upside$67.86 Price TargetShort InterestBearish14.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.78Based on 7 Articles This WeekInsider TradingSelling Shares$1.04 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.58) to ($5.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector150th out of 939 stocksDiagnostic Substances Industry3rd out of 13 stocks 3.4 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $67.86, Intellia Therapeutics has a forecasted upside of 150.6% from its current price of $27.08.Amount of Analyst CoverageIntellia Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.05% of the outstanding shares of Intellia Therapeutics have been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 6.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Intellia Therapeutics is -0.67. Previous Next 3.8 News and Social Media Coverage News SentimentIntellia Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Intellia Therapeutics this week, compared to 4 articles on an average week.Search Interest49 people have searched for NTLA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows20 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,037,955.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.58) to ($5.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Intellia Therapeutics Stock (NASDAQ:NTLA)Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More NTLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTLA Stock News HeadlinesMarch 28, 2024 | fool.comBetter Cathie Wood Stock: Moderna vs. IntelliaMarch 22, 2024 | marketwatch.comIntellia Therapeutics Ends Co-Development Agreement With RegeneronMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 22, 2024 | msn.comIntellia opts out of hemophilia pact with RegeneronMarch 21, 2024 | investorplace.comHot Stocks: The 3 Best Opportunities for Investing in BiotechMarch 21, 2024 | investorplace.com3 Stocks That Could Be the Next Big Thing in Gene EditingMarch 20, 2024 | investing.comIntellia begins phase 3 trial for CRISPR therapy NTLA-2001March 18, 2024 | globenewswire.comIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 18, 2024 | americanbankingnews.comIntellia Therapeutics, Inc. Expected to Post FY2026 Earnings of ($7.54) Per Share (NASDAQ:NTLA)March 9, 2024 | fool.comIs Intellia Therapeutics Stock a Buy Now?March 6, 2024 | fool.comIntellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street AnalystFebruary 29, 2024 | seekingalpha.comIntellia Therapeutics Is On The MoveFebruary 29, 2024 | fool.comA Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right NowFebruary 27, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)February 26, 2024 | markets.businessinsider.comHold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive DynamicsFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial HealthFebruary 25, 2024 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowFebruary 24, 2024 | realmoney.thestreet.comIntellia Therapeutics just downgraded at Goldman Sachs, here's whyFebruary 24, 2024 | msn.comGoldman Sachs Downgrades Intellia Therapeutics (NTLA)February 23, 2024 | markets.businessinsider.comStrong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial StandingFebruary 23, 2024 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | markets.businessinsider.comIntellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical MilestonesFebruary 22, 2024 | finance.yahoo.comQ4 2023 Intellia Therapeutics Inc Earnings CallFebruary 22, 2024 | finance.yahoo.comIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 22, 2024 | globenewswire.comIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressSee More Headlines Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NTLA CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees526Year FoundedN/APrice Target and Rating Average Stock Price Target$67.86 High Stock Price Target$107.00 Low Stock Price Target$29.00 Potential Upside/Downside+154.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,190,000.00 Net Margins-893.34% Pretax Margin-1,326.51% Return on Equity-43.91% Return on Assets-36.42% Debt Debt-to-Equity RatioN/A Current Ratio8.67 Quick Ratio8.67 Sales & Book Value Annual Sales$36.28 million Price / Sales70.70 Cash FlowN/A Price / Cash FlowN/A Book Value$11.73 per share Price / Book2.28Miscellaneous Outstanding Shares96,110,000Free Float93,223,000Market Cap$2.57 billion OptionableOptionable Beta1.80 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. John M. Leonard M.D. (Age 67)President, CEO & Director Comp: $1.06MMr. Glenn G. Goddard CPA (Age 53)Executive VP, CFO & Treasurer Comp: $630.91kDr. Laura Sepp-Lorenzino Ph.D. (Age 63)Executive VP & Chief Scientific Officer Comp: $670.58kMr. James E. Basta Esq. (Age 58)J.D., Executive VP, General Counsel & Corporate Secretary Comp: $616.15kDr. David Lebwohl M.D. (Age 69)Executive VP & Chief Medical Officer Comp: $671.42kMr. Derek Hicks (Age 51)Executive VP & Chief Business Officer Comp: $823.42kMr. Nessan Bermingham Ph.D. (Age 51)Founder & Member of Scientific Advisor Board Comp: $1.38MDr. Rachel E. Haurwitz Ph.D. (Age 38)Co-Founder Dr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardDr. Jennifer A. Doudna Ph.D. (Age 59)Founder & Member of Scientific Advisor Board More ExecutivesKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXMyriad GeneticsNASDAQ:MYGNQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 7,151 shares on 3/22/2024Ownership: 0.011%Healthcare of Ontario Pension Plan Trust FundBought 298,000 shares on 3/21/2024Ownership: 0.310%Vanguard Group Inc.Bought 155,579 shares on 3/11/2024Ownership: 8.685%Wellington Management Group LLPSold 195,077 shares on 3/5/2024Ownership: 2.556%James BastaSold 2,297 sharesTotal: $75,778.03 ($32.99/share)View All Insider TransactionsView All Institutional Transactions NTLA Stock Analysis - Frequently Asked Questions Should I buy or sell Intellia Therapeutics stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares. View NTLA analyst ratings or view top-rated stocks. What is Intellia Therapeutics' stock price target for 2024? 14 Wall Street analysts have issued 1 year price objectives for Intellia Therapeutics' stock. Their NTLA share price targets range from $29.00 to $107.00. On average, they predict the company's share price to reach $67.86 in the next twelve months. This suggests a possible upside of 150.6% from the stock's current price. View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts. How have NTLA shares performed in 2024? Intellia Therapeutics' stock was trading at $30.49 at the beginning of the year. Since then, NTLA stock has decreased by 11.2% and is now trading at $27.08. View the best growth stocks for 2024 here. When is Intellia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NTLA earnings forecast. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, February, 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. The firm earned ($1.92) million during the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 43.91% and a negative net margin of 893.34%. During the same quarter in the previous year, the company earned ($1.40) earnings per share. What ETFs hold Intellia Therapeutics' stock? ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Horizon Kinetics Medical ETF (MEDX), ARK Innovation ETF (ARKK), iShares Genomics Immunology and Healthcare ETF (IDNA) and Franklin Genomic Advancements ETF (HELX). What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO? 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO). When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.74%), Vanguard Group Inc. (9.32%), Vanguard Group Inc. (8.69%), Sumitomo Mitsui Trust Holdings Inc. (3.88%), Nikko Asset Management Americas Inc. (3.88%) and Wellington Management Group LLP (2.56%). Insiders that own company stock include Caroline Dorsa, David Lebwohl, Eliana Clark, Glenn Goddard, James Basta, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Muna Bhanji. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTLA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.